Guideline Recommendations for Intravenous Albumin Therapy

Evidence‑Based Indications (Use Albumin)

• Large‑volume paracentesis (≥5 L) in cirrhosis – Conditionally recommend albumin to prevent paracentesis‑induced circulatory dysfunction; typical dose 6–8 g per litre of ascites removed (or a fixed 20–40 g). Evidence certainty is very low; albumin reduces post‑paracentesis circulatory dysfunction (RR 1.98, 95 % CI 1.31–2.99) compared with other plasma expanders. – American College of Chest Physicians 1

• Spontaneous bacterial peritonitis (SBP) in cirrhosis – Conditionally recommend albumin together with antibiotics. Regimen: 1.5 g/kg on day 1, then 1.0 g/kg on day 3. Albumin lowers the risk of renal impairment (OR 0.21, 95 % CI 0.11–0.42) and mortality (OR 0.34, 95 % CI 0.19–0.60). In the largest trial (126 patients) kidney impairment occurred in 10 % vs 33 % (P = 0.002) and in‑hospital mortality 10 % vs 29 % (P = 0.01) with albumin. Evidence certainty is low to moderate. – American College of Chest Physicians 1

• Hepatorenal syndrome (type 1/AKI‑HRS) in cirrhosis – Albumin is the preferred volume expander when combined with a vasoconstrictor (e.g., terlipressin, norepinephrine, or octreotide/midodrine). Suggested dose: 1 g/kg/day for two consecutive days (maximum 100 g/day). The ICTMG guideline refrains from a formal recommendation because trials have compared albumin versus albumin, leaving comparative evidence insufficient. – International Consensus on the Treatment of Hepatorenal Syndrome (ICTMG) 2

Contraindications in Critical‑Care Settings (Do NOT Use Albumin)

• General ICU patients (excluding burns and ARDS) – Do not use albumin for first‑line volume replacement or to raise serum albumin levels; crystalloids are preferred and more cost‑effective. Evidence certainty is moderate; no mortality benefit versus crystalloids (RR 1.02, 95 % CI 0.96–1.10). – American College of Chest Physicians 1

• Thermal injuries and ARDS – Do not use albumin for volume replacement or serum albumin augmentation. Evidence certainty is very low. – American College of Chest Physicians 2

• Sepsis and septic shock – Do not use albumin as first‑line therapy. Trials show no mortality or renal‑replacement‑therapy benefit compared with crystalloids, and in cirrhotic patients with septic hypotension (studies of 308 and 100 patients) albumin did not improve 7‑day or 28‑day survival. Albumin was associated with higher pulmonary‑edema rates (OR 5.17, 95 % CI 1.62–16.47). – American Society of Anesthesiologists 3

• Extravascular fluid removal with diuretics in critically ill patients – Do not add albumin to diuretic regimens for fluid removal; evidence (very low certainty) shows no meaningful difference in net daily fluid balance (mean difference ‑0.22 L/day, 95 % CI ‑0.88 to 0.43). – American College of Chest Physicians 2

Contraindications in Specific Populations

• Preterm neonates (≤36 weeks gestation) – Do not use albumin to improve respiratory function or for volume replacement in infants ≤32 weeks or ≤1,500 g, regardless of perfusion status. Evidence certainty is very low. – American College of Chest Physicians 2

• Pediatric cardiac surgery – Do not use albumin for priming cardiopulmonary‑bypass circuits or peri‑operative volume replacement. Evidence certainty is very low. – American College of Chest Physicians 2

• Hemodialysis – Do not use albumin to prevent or treat intradialytic hypotension or to enhance ultrafiltration efficiency. Evidence certainty is very low. – American College of Chest Physicians 2

• Chronic hypoalbuminemia (e.g., cirrhosis, malabsorption, generalized malnutrition) – Albumin is not indicated as a protein‑nutrition source; low serum albumin alone does not justify albumin administration. – American College of Chest Physicians 4

• Cirrhosis with extraperitoneal infections – Do not routinely give albumin; it does not improve mortality or renal outcomes versus antibiotics alone and increases pulmonary‑edema risk (OR 5.17, 95 % CI 1.62–16.47). – American College of Chest Physicians 1

Safety and Cost Considerations

• Adverse effects – Rapid infusion of 25 % albumin in hypoproteinemic patients can precipitate pulmonary edema. – American College of Chest Physicians 1

• Cost – Approximate price is US $130 per 25 g of albumin, substantially higher than crystalloids, with no proven clinical benefit in most scenarios. – American College of Chest Physicians 4

Guideline Summary for Intravenous Albumin Use

1. Indications in Cirrhosis (Evidence‑Based)

• Large‑volume paracentesis (>5 L) – Albumin is conditionally recommended to prevent procedure‑induced circulatory dysfunction in hospitalized patients with cirrhosis and ascites. Evidence certainty: very low. [5][6][7][8]
• Spontaneous bacterial peritonitis (SBP) – Albumin is conditionally recommended in addition to antibiotics for SBP. Evidence certainty ranges from very low to moderate. [5][9]6
• SBP dosing & outcomes – A regimen of 1.5 g/kg at diagnosis followed by 1 g/kg on day 3 reduces mortality and the incidence of renal failure in this population. 10
• Hepatorenal syndrome – type LRA (SHR‑LRA) – Albumin is the preferred volume expander for hospitalized cirrhotic patients with ascites who develop acute kidney injury. Recommended dose: 1 g/kg/day for two consecutive days (maximum 100 g/day), administered together with a vasoconstrictor (e.g., terlipressin, norepinephrine, or octreotide/midodrine). 10

2. Contraindications in Critical Care (Adult ICU)

• General critically ill adults (excluding burns and ARDS) – Albumin is not suggested as first‑line volume replacement or to raise serum albumin levels; crystalloids are preferred and more cost‑effective. Evidence certainty: moderate. [5][9]6
• Thermal injuries and ARDS – Albumin is not suggested for volume replacement or serum albumin augmentation. Evidence certainty: very low. [9][7]8
• Extravascular fluid removal – Combining albumin with diuretics for fluid removal in critically ill patients is not recommended. Evidence certainty: very low. [7][8]

3. Pediatric and Neonatal Considerations

• Premature neonates – Albumin is not recommended to improve respiratory function in preterm infants with respiratory distress and hypoalbuminemia, nor for volume replacement in preterms with or without hypoperfusion. [7][8]
• Pediatric cardiac surgery – Albumin is not recommended for priming cardiopulmonary bypass circuits or for peri‑operative volume replacement. [7][8]

4. Renal Replacement Therapy

• Hemodialysis – Albumin is not recommended to prevent or treat intradialytic hypotension or to enhance ultrafiltration efficiency. Evidence certainty: very low. [7][8]10

5. Chronic Hypoalbuminemia (Nutritional Use)

• Albumin should not be used as a protein‑nutrition source in chronic conditions such as cirrhosis, malabsorption syndromes, or generalized malnutrition. [10][7]

6. Risks and Adverse Effects

• Hypotension – Albumin infusion can precipitate low blood pressure. 7
• Hemodilution‑related hemolysis – May require red‑blood‑cell transfusion. 6
• Peripheral gangrene – Resulting from dilution of natural anticoagulants. 5

7. Cost‑Effectiveness

• Acquisition cost – Approximately US $130 per 25 g of albumin. [5][9]6
• Economic comparison – Albumin is substantially more expensive than crystalloids and provides no proven benefit in the majority of clinical scenarios. [5][9]

Plasma Volume Expansion: Crystalloid Preferred Over Albumin

Primary Recommendation

• For adults with increased interstitial fluid who need plasma volume expansion, isotonic balanced crystalloids (e.g., lactated Ringer’s) should be used as first‑line therapy rather than albumin 11.

Evidence of No Mortality or Renal Benefit with Albumin

• Systematic reviews of ≈ 26,000 critically ill adults show that albumin provides no survival advantage compared with crystalloids (risk ratio 1.02; 95 % CI 0.96‑1.10) 11.
• The same reviews demonstrate that albumin does not reduce the need for renal replacement therapy (risk ratio 1.11; 95 % CI 0.96‑1.27) 11.

Guideline Consensus

• The 2024 International Collaboration for Transfusion Medicine Guidelines conditionally recommend against using albumin for general plasma‑volume expansion in critically ill adults (moderate‑certainty evidence) 11.

Contraindications for Albumin in General Critical Care

• Albumin should not be used for routine ICU volume replacement because it offers no benefit over crystalloids 11.
• In patients with traumatic brain injury, albumin administration is associated with higher mortality (risk ratio 1.62; 95 % CI 1.12‑2.34) 11.

Situations Where Albumin May Be Considered

• Albumin may be used only in cirrhotic patients undergoing large‑volume paracentesis, those with spontaneous bacterial peritonitis, or those with hepatorenal syndrome; in all other scenarios, balanced crystalloids remain the preferred fluid 11.

Absolute and Conditional Indications for Albumin Infusion in Cirrhosis

1. Absolute Indications (strong evidence) – International Collaboration for Transfusion Medicine Guidelines (ICTMG)

• Large‑volume paracentesis (≥5 L) in patients with cirrhosis warrants albumin infusion to prevent paracentesis‑induced circulatory dysfunction. The ICTMG lists this as one of only two absolute indications with strong evidence. [12][13]14

• Spontaneous bacterial peritonitis (SBP) in cirrhosis requires albumin together with antibiotics. The ICTMG recommends routine albumin use in all cirrhotic patients diagnosed with SBP. [12][13]14

2. Evidence Supporting the Absolute Indications

The above effect estimates are drawn from the ICTMG‑endorsed meta‑analyses. 15

Largest SBP trial (126 patients)

These results underpin the strong recommendation for albumin in SBP. 15

3. Conditional Indications – ICTMG & Surviving Sepsis Campaign

3.1 Hepatorenal Syndrome (Type 1 / AKI‑HRS)

• Albumin is the preferred volume expander when combined with vasoconstrictors (e.g., terlipressin, norepinephrine, octreotide/midodrine).

3.2 Sepsis / Septic Shock Requiring Massive Crystalloid Resuscitation

• Consider albumin only after large volumes of crystalloids have been given.

• Recent trials in cirrhotic patients with septic hypotension (308 + 100 patients) showed no survival benefit and a higher risk of pulmonary edema.

4. Contraindications Supported by Evidence

• In cirrhosis with extraperitoneal infections, albumin increases the risk of pulmonary edema without improving mortality or renal outcomes. This finding is derived from the same trial data that evaluated SBP. 15

5. FDA‑Labeled Indication (historical)

• Acute liver failure is listed on the FDA label for albumin, although current evidence‑based guidelines do not endorse its routine use for this condition. 13

All bullet points include at least one citation identifier and reflect the strength of the underlying evidence as reported in the 2024 International Collaboration for Transfusion Medicine Guidelines and the Surviving Sepsis Campaign.